Perhaps only modestly in severely depressed patients, say the results of a recent meta-analysis.
Perhaps only modestly in severely depressed patients, say the results of a recent meta-analysis.
The findings are based on data obtained from all published and unpublished clinical trials submitted to the Food and Drug Administration (FDA) for the licensing of four selective serotonin or serotonin-noradrenaline reuptake inhibitors: fluoxetine (Prozac), venlafaxine (Effexor), nefazodone (Serzone), and paroxetine (Seroxat, Paxil). The study focused on the degree to which patients improved compared with placebo and relative to the initial severity of their disease. Including unpublished data helped to eliminate bias that can occur when unpublished negative trials are excluded from analysis.
The researchers found almost no difference between the effects of the drugs and placebo in patients with moderate or mild depression at baseline. And while efficacy reached clinical significance in the most extremely depressed patients, it was due to a decrease in response to placebo and not to an increase in response to medication.
Because the data submitted to the FDA reached statistical significance for the effects of the drugs compared with placebo, but not clinical significance and because more than 40 million people worldwide have been treated with fluoxetine alone, the authors of the meta-analysis concluded by suggesting that the criteria for licensing these drugs be changed.
Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:260-268.
Prenatal cannabis use not linked to offspring ASD development
November 1st 2024In a recent study, adjustments for maternal characteristics mediated the association between maternal prenatal cannabis use and offspring autism spectrum disorder, indicating no statistically significant increase in risk.
Read More
Preference for alternative contraceptive sources reported by many patients
October 31st 2024With nearly half of short-acting contraceptive users preferring non-traditional sources such as telehealth and over-the-counter options, a recent study highlights evolving patient needs in contraceptive access.
Read More
Importance of reproductive health services for adolescents during the COVID-19 pandemic
October 30th 2024In a recent study, high rates of reproductive health service use were reported among adolescent mothers, indicating the benefits of this model for providing care when other options are unavailable.
Read More